Skip to content

EBIT at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$33M+140%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
-$6.12M+76.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
Glaukos logo
GlaukosGKOS
AbbVie logo
AbbVieABBV
Boston Scientific logo
Boston ScientificBSX

Other financials

Income statement

See full
Revenue$19.7M+12.5%
Gross profit$17.0M+12.5%
Operating income-$12.4M+10.4%
Net income-$13.0M+8.3%
EPS (diluted)-$0.24+14.3%

Balance sheet

See full
Cash & equivalents$85.0M-21.9%
Total debt$40.9M+1.1%
Total equity$53.9M-30.6%
Total assets$109.7M-15.4%

Cash flow

See full
Operating cash flow-$7.0M+39.4%
CapEx$60.0K
Free cash flow-$7.1M+38.9%

Valuation

See full
Market cap$294.9M+35.0%
Enterprise value$250.83M+59.0%
P/S3.7×+0.8×

Profitability

See full
Gross margin86.2%+0.5pp
Operating margin-44.8%-10.2pp
Net margin-46.8%-9.6pp
FCF margin-31.9%+0.2pp

Returns & leverage

See full
Return on equity-56.6%+4.3pp
Debt / equity0.8×+0.2×
Current ratio5.9×-4.6×

Where this comes from

Calculated from Sight Sciences, Inc.’s reported figures.

The official record: Sight Sciences, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sight Sciences, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sight Sciences, Inc.'s EBIT?
Sight Sciences, Inc. (SGHT) reported EBIT of -$12.41M in Q1 2026.
How has Sight Sciences, Inc.'s EBIT changed year-over-year?
Sight Sciences, Inc.'s EBIT increased by 10.4% year-over-year, from -$13.86M to -$12.41M.
What is the long-term trend for Sight Sciences, Inc.'s EBIT?
Over 4 years (2021 to 2025), Sight Sciences, Inc.'s EBIT has grown at a -7.9% compound annual growth rate (CAGR), from -$51.48M to -$37.1M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.